Compare Quest Diagnostics Inc (DGX) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs EPR Properties — how do they compare? Quest Diagnostics Inc trades at $205.66 (market cap $22.80B), while EPR Properties trades at $59.95 (market cap $4.56B). The key difference: Quest Diagnostics Inc is far larger — about 5× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.25%). Which is the better fit depends on your goals.
| DGX | EPR | |
|---|---|---|
Market Cap | $22.80B | $4.56B |
Sector | Health | Real Estate |
52-Week High | $216.02 | $60.81 |
52-Week Low | $166.42 | $48.71 |
Enterprise Value | $28.82B | $7.62B |
Dividend Yield | 1.67% | 6.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EPR Properties trades at $59.81, up 0.32% today, with a bullish technical signal from moving averages and strong fundamentals including a 39.93% net income margin and consistent dividend payments. Recent earnings show mixed results with a Q1 2026 miss but previous quarters beating expectations. The company maintains robust cash flow from operations of $421 million in 2025 and high portfolio occupancy.
Outlook remains positive with a consensus price target of $63.00, though risks include reliance on experiential real estate and market sensitivity. The stock offers a compelling blend of income and growth, supported by analyst buy ratings and recent acquisitions like the Six Flags park deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
